Literature DB >> 26984362

Nuclear medicine for imaging of epithelial ovarian cancer.

Seyed Mohammad Abedi1, Alireza Mardanshahi1, Roza Shahhosseini2, Seyed Jalal Hosseinimehr3,4.   

Abstract

Cancer is one of the leading causes of mortality worldwide. Usually, the diagnosis of cancer at an early stage is important to facilitate proper treatment and survival. Nuclear medicine has been successfully used in the diagnosis, staging, therapy and monitoring of cancers. Single-photon emission computed tomography and PET-based companion imaging agents are in development for use as a companion diagnostic tool for patients with ovarian cancer. The present review discusses the basic and clinical studies related to the use of radiopharmaceuticals in the diagnosis and management of ovarian cancer, focusing on their utility and comparing them with other imaging techniques such as computed tomography and MRI.

Entities:  

Keywords:  diagnosis; epithelial ovarian cancer; imaging; nuclear medicine; radiopharmaceutical

Mesh:

Substances:

Year:  2016        PMID: 26984362     DOI: 10.2217/fon.16.19

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  2 in total

1.  99mTc-radiolabeled GE11-modified peptide for ovarian tumor targeting.

Authors:  Najmeh Rahmanian; Seyed Jalal Hosseinimehr; Ali Khalaj; Zohreh Noaparast; Seyed Mohammad Abedi; Omid Sabzevari
Journal:  Daru       Date:  2017-05-02       Impact factor: 3.117

2.  99mTc-Glucarate for assessment of paclitaxel therapy in human ovarian cancer in mice.

Authors:  Hossein Sadeghi; Najmeh Rahmanian; Fereshteh Talebpour Amiri; Hossein Amirfakhrian; Seyed Mohammad Abedi; Seyed Jalal Hosseinimehr
Journal:  Iran J Basic Med Sci       Date:  2018-01       Impact factor: 2.699

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.